No valuation for Phrontline Biopharma is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($99.7M) and the funding record below are the closest available signals.
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Phrontline Biopharma
- ·The full record, as it builds
Funding history
No funding rounds for Phrontline Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
How Phrontline Biopharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Phrontline Biopharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Phrontline Biopharma raised?
- Phrontline Biopharma has raised $99.7M in total funding across its recorded rounds.